Why industry should register and disclose results of clinical studies—perspective of a recovering academicBMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7497.959 (Published 21 April 2005) Cite this as: BMJ 2005;330:959
- Jesse A Berlin, senior director, statistical science (email@example.com)1
- 1 Johnson & Johnson Pharmaceutical Research and Development, LLC, 1125 Trenton-Harbourton Road, PO Box 200, Titusville, NJ 08560, USA
Although it's not typical, in a scholarly publication such as the BMJ, to add a personal perspective to a commentary, I believe that in this situation my background is relevant to the discussion. My doctoral dissertation, written in 1988, dealt with the topic of publication bias, which was well described in the Ottawa statement appearing in this issue.1 Since then, I've contributed to several studies of factors affecting publication, including an early empirical demonstration of publication bias.2
About six months ago, I moved from a university, where I had spent 15 years, to a position in a large pharmaceutical research and development group. Registration and disclosure of the results of clinical studies have, not surprisingly, been topics of numerous conversations where I work.